Adjuvant gonadotropin-releasing hormone analogues for chemotherapy induced premature ovarian failure in premenopausal women

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Chen, Hengxi ^b   Lina, Hu ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN DERIVATIVE; GOSERELIN; LEUPRORELIN; PLACEBO; TRIPTORELIN;

CANCER SURVIVAL; CHEMOTHERAPY INDUCED PREMATURE OVARIAN FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ESTROGEN BLOOD LEVEL; FEMALE; FOLLITROPIN RELEASE; HEADACHE; HOT FLUSH; HUMAN; LUTEINIZING HORMONE RELEASE; MENSTRUATION; OSTEOPOROSIS; PREGNANCY RATE; PREMATURE OVARIAN FAILURE; PREMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SELF ESTEEM; SENSITIVITY ANALYSIS; SIDE EFFECT; VASOMOTOR DISORDER;

EID: 77950180314     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008018     Document Type: Review

References (47)

1. Ataya 1985 Ataya M, McKanna JA,Weintraub AM, Clark MR, LeMaire WJ. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Research 1985;45:3651-6.
2. Ataya 1989 Ataya K, Moghissi K. Chemotherapy-induced premature ovarian failure: mechanisms and prevention. Steroids 1989;54:607- 26.
3. Ataya 1993 Ataya K, Ramahi-Ataya A. Reproductive performance of female rats treated with cyclophosphamide and/or LHRH agonist. Reproductive Toxicology 1993;7:229-35.
4. Ataya 1995 Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biology of Reproduction 1995;52:365-72.
5. Behringer 2005 Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, et al.A report from the German Hodgkin's Lymphoma StudyGroup. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen and the use of oral contraceptives during therapy. Journal of Clinical Oncology 2005;23:7555-64.
6. Bines 1996 Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology 1996;14:1718-29.
7. Blumenfeld 1996 Blumenfeld Z Avivi I Linn S Epelbaum R Ben-Shahar M Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Human Reproduction 1996;11(8):1620-6.
8. Blumenfeld 1999 Blumenfeld Z, Avivi I, Ritter M, Rowe JM. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. Journal of the Society for Gynecologic Investigation 1999;6:229-39.
9. Blumenfeld 2000 Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000;9:1-5.
10. Blumenfeld 2007 Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy?The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. The Oncologist 2007;12:1044-54.
11. Blumenfeld 2008a Blumenfeld Z, Avivi I, Eckman A, Epelbaum R, Rowe JM, Dann EJ. Gonadotropin releasing hormone agonist decreases chemotherapy induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertility and Sterility 2008;89:166-73.
12. Blumenfeld 2008b Blumenfeld Z, von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Human Reproduction Update 2008;14:543-52.
13. Bokser 1990 Bokser L, Szende B, Schally AV. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophospamide-induced gonadotoxicity in female rats. British Journal of Cancer 1990;61:861-5.
14. Brincker 1987 Brincker H, Rose C, Rank F, Mouridsen HT, Jakobsen A, Dombernowsky P, et al.Evidence of castration mediate effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. Journal of Clinical Oncology 1987;5:1771-8.
15. Byrne 1992 Byrne J, Fears TR, Gail MH, Pee D, Connelly RR, Austin DF, et al.Early menopause in long-term survivors of cancer during adolescence. American Journal of Obstetrics and Gynecology 1992; 166:788-93.
16. Chapman 1979 Chapman RM, Sutcliffe SB, Malpas JS. Cytotoxic induced ovarian failure in women with Hodgkin's disease. I. Hormonal function. JAMA 1979;242:1877-81.
17. Chiarelli 1999 Chiarelli AM, Marrett LD, Darlington G. Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964-1988 in Ontario, Canada. American Journal of Epidemiology 1999;150:245-54.
18. Couzinet 1991 Couzinet B, Lahlou N, Thomas G, Thalabard JC, Bouchard P, Roger M, et al.Effects of gonadotrophin releasing hormone antagonist and agonist on the pulsatile release of gonadotrophins and alpha-subunit in postmenopausal women. Clinical Endocrinology 1991;34:477-83.
19. Danforth 2005 Danforth DR, Arbogast LK, Friedman CI. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists. Fertility and Sterility 2005;83:1333-8.
20. Del Mastro 2006 Del Mastro L, Catzeddu T, Boni L, Bell C, Sertoli MR, Bighin C, et al.Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young early breast cancer patients. Annals of Oncology 2006;17:74-8.
21. Falcone 2005 Falcone T, Bedaiwy MA. Fertility preservation and pregnancy outcome after malignancy. Current Opinion in Obstetrics and Gynecology 2005;17:21-26.
22. Glode 1981 Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1981;1:1132-4.
23. Goldhirsch 1990 Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine of adjuvant chemotherapy for premenopausal breast cancer patients. Annals of Oncology 1990;1:183-8.
24. Goodwin 1999 Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. Journal of Clinical Oncology 1999;17:2365-70.
25. Higgins 2008 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
26. Huser 2008 Huser M, Crha I, Ventruba P, Hudecek R, Zakova J, Smardova L, et al.Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients. Human Reproduction 2008;23:863-8.
27. Imai 2007 Imai A, Sugiyama M, Furui T, Tamaya T, Ohno T. Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecologic and Obstetric Investigation 2007;63:102-6.
28. Koyama 1977 Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977;39:1403-9.
29. Kreuser 1987 Kreuser ED, Xiros N, Hetzel WD, Heimpel H. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy forHodgkin's disease. Journal of Cancer Research and Clinical Oncology 1987;113:260-6.
30. Larsen 2003 Larsen EC, Muller J, Schmiegelow K, Rechnitzer C, Andersen AN. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. The Journal of Clinical Endocrinology and Metabolism 2003;88(11):5307-14.
31. Lutchman Singh 2005 Lutchman Singh K, Davies M, Chatterjee R. Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Human Reproduction Update 2005;11:69-89.
32. Mardesic 2004 Mardesic T, SnajderovaM, Sramkova L, Keslova P, Sedlacek P, Stary J. Protocol combining GnRH agonists and GnRH antagonists for rapid suppression and prevention of gonadal damage during cytotoxic therapy. European Journal of Gynaecological Oncology 2004;25:90-2.
33. Matikainen 1992 Matikainen T, Ding YQ, Vergara M, Huhtainiemi I, Couzinet B, Schaison G. Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone antagonist and agonist treatments in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 1992;75:820-5.
34. Meirow 1999 Meirow D, Lewis H, Nugent D, Epstein M. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Human Reproduction 1999;14:1903-7.
35. Meirow 2001 Meirow D, Nugent D. The eddects of radiotherapy and chemotherapy on female reproduction. Human Reproduction Update 2001;7:535-43.
36. Meirow 2004 Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Human Reproduction 2004;19(6):1294-9.
37. Moore 2000 Moore HC. Following treatment for breast cancer. The incidence of treatment-related amenorrhea is related to patient age and to the treatment regimen. Current Oncology Reports 2000;2:587-93.
38. Ortin 1990 Ortin TT, Shostak CA, Donaldson SS. Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Standord experience. International Journal of Radiation Oncology, Biology, Physics 1990;19:873-80.
39. Peng 2007 Peng P, Yang DZ, Zheng CY, Mo YQ, He YM, Zhang QX. Effects of gonadotropin releasing hormone analogues on chemotherapy-induced ovarian function damage in rat. Zhonghua Fu Chan Ke Za Zhi 2007;42:546-50.
40. Rabinovici 1992 Rabinovici J, Rothman P, Monroe SE, Nerenberg C, Jaffe RB. Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (Ganirelix) with minimal histamine-releasing properties: studies in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 1992;75: 1220-5.
41. Recchia 2006 Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, Candeloro G, et al.Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006;106:514-23.
42. Rivkees 1988 Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 1988;259:2123-5.
43. Sobrinho 1971 Sobrinho LG, Levine RA, DeConti RC. Amenorrhea inpatients with Hodgkin's disease treated with anti-neoplastic agents. Amarican Journal of Obstetric and Gynecology 1971;109:135-9.
44. Somers 2005 Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis and Rheumatism 2005;52:2761-7.
45. Tangir 2003 Tangir J, Zelterman D, Ma W, Schwartz PE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstetric and Gynecology 2003;101:251-7.
46. Urruticoechea 2008 Urruticoechea A, Arnedos M, Walsh G, Dowsett M, Smith IE. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast Cancer Research and Treatment 2008;110:411-6.
47. Warne 1973 Warne GL, Fairley KF, Hobbs JB, Martin FI. Cyclophosphamide-induced ovarian failure. New England Journal of Medicine 1973; 289:1159-62.